Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

Arterial Disease Multifactorial Intervention Trial (ADMIT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00000539
Recruitment Status : Completed
First Posted : October 28, 1999
Last Update Posted : July 12, 2016
Information provided by:
National Heart, Lung, and Blood Institute (NHLBI)

Brief Summary:
To evaluate, in asymptomatic and symptomatic participants with peripheral arterial disease, the feasibility of recruitment and adherence, efficacy and safety of HDL-C raising along with effective control of LDL-C levels, antioxidant therapy, antithrombotic therapy, and their combinations.

Condition or disease Intervention/treatment Phase
Arterial Occlusive Diseases Cardiovascular Diseases Heart Diseases Vascular Diseases Diabetes Mellitus Drug: niacin Drug: pravastatin Drug: beta-carotene Drug: vitamin E Behavioral: dietary supplements Drug: vitamin C Drug: warfarin Phase 3

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Allocation: Randomized
Primary Purpose: Treatment
Study Start Date : September 1992
Actual Study Completion Date : March 1999

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Men and women with symptomatic or asymptomatic peripheral arterial disease.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00000539

Sponsors and Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
Layout table for investigator information
OverallOfficial: Kathryn Davis Statistics and Epidemiology Research Corporation

Layout table for additonal information Identifier: NCT00000539    
Other Study ID Numbers: 82
First Posted: October 28, 1999    Key Record Dates
Last Update Posted: July 12, 2016
Last Verified: January 2006
Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Diseases
Vascular Diseases
Arterial Occlusive Diseases
Cardiovascular Diseases
Vitamin E
Beta Carotene
Growth Substances
Physiological Effects of Drugs
Molecular Mechanisms of Pharmacological Action
Protective Agents
Hypolipidemic Agents
Lipid Regulating Agents
Anticholesteremic Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Enzyme Inhibitors